Table 2 Univariate and multivariate analysis of progression-free survival.

From: Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling

Clinical character

Category

No.of patients

Univariate analysis

Multivariate analysis

Mean

95% CI

P value

HR (95% CI)

P value

BARD1 expression

Low

63

53.01

44.29–61.73

0.002

1.769 (1.184–2.644)

0.005

High

146

34.86

29.23–40.49

Gender

Female

33

42.42

31.42–53.42

0.344

  

Male

176

39.47

34.28–44.67

Age (years)

≤55

141

39.80

33.92–45.69

0.754

  

>55

68

41.74

33.13–50.34

Family history

No

176

38.86

33.60–44.12

0.170

  

Yes

33

48.85

36.88–60.83

HBsAg

Negative

39

37.92

26.89–48.94

0.863

  

Positive

170

40.86

35.45–46.27

Median size (range, cm)

≤5

73

62.47

55.22–69.72

<0.001

2.420 (1.468–3.991)

0.001

>5

136

28.60

23.20–33.99

Cirrhosis

No

20

37.32

21.97–52.66

0.687

  

Yes

189

40.77

35.65–45.89

Tumor number

Single

141

46.61

40.64–52.58

<0.001

1.173 (0.727–1.894)

0.513

Multiple

68

27.08

19.75–34.41

Wine-drinking

No

103

45.19

37.84–52.54

0.125

  

Yes

106

36.44

30.14–42.75

TNM stage

I–II

91

55.82

48.91–62.73

<0.001

1.698 (1.026–2.809)

0.039

III–IV

118

28.54

22.62–34.47

Metastasis

No

178

41.98

36.67–47.29

0.122

  

Yes

31

30.57

19.58–41.56

BCLC stage

0-A

96

55.24

48.29–62.20

<0.001

1.156 (0.631–2.116)

0.639

B–C

113

27.68

21.88–33.48

AFP (ng/ml)

≤100

84

44.22

36.53–51.90

0.177

  

>100

125

37.97

31.73–44.20

AST (U/L)

≤40

97

54.56

47.42–61.69

<0.001

1.664 (1.072–2.582)

0.023

>40

112

28.51

22.79–34.23

  1. HR, hazard ratio; CI, confidence interval.
Back to article page